Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults
Top Cited Papers
- 4 March 2010
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 362 (9) , 800-811
- https://doi.org/10.1056/nejmoa0908359
Abstract
Fasting glucose is the standard measure used to diagnose diabetes in the United States. Recently, glycated hemoglobin was also recommended for this purpose. We compared the prognostic value of glycated hemoglobin and fasting glucose for identifying adults at risk for diabetes or cardiovascular disease. We measured glycated hemoglobin in whole-blood samples from 11,092 black or white adults who did not have a history of diabetes or cardiovascular disease and who attended the second visit (occurring in the 1990–1992 period) of the Atherosclerosis Risk in Communities (ARIC) study. The glycated hemoglobin value at baseline was associated with newly diagnosed diabetes and cardiovascular outcomes. For glycated hemoglobin values of less than 5.0%, 5.0 to less than 5.5%, 5.5 to less than 6.0%, 6.0 to less than 6.5%, and 6.5% or greater, the multivariable-adjusted hazard ratios (with 95% confidence intervals) for diagnosed diabetes were 0.52 (0.40 to 0.69), 1.00 (reference), 1.86 (1.67 to 2.08), 4.48 (3.92 to 5.13), and 16.47 (14.22 to 19.08), respectively. For coronary heart disease, the hazard ratios were 0.96 (0.74 to 1.24), 1.00 (reference), 1.23 (1.07 to 1.41), 1.78 (1.48 to 2.15), and 1.95 (1.53 to 2.48), respectively. The hazard ratios for stroke were similar. In contrast, glycated hemoglobin and death from any cause were found to have a J-shaped association curve. All these associations remained significant after adjustment for the baseline fasting glucose level. The association between the fasting glucose levels and the risk of cardiovascular disease or death from any cause was not significant in models with adjustment for all covariates as well as glycated hemoglobin. For coronary heart disease, measures of risk discrimination showed significant improvement when glycated hemoglobin was added to models including fasting glucose. In this community-based population of nondiabetic adults, glycated hemoglobin was similarly associated with a risk of diabetes and more strongly associated with risks of cardiovascular disease and death from any cause as compared with fasting glucose. These data add to the evidence supporting the use of glycated hemoglobin as a diagnostic test for diabetes.This publication has 49 references indexed in Scilit:
- Elevated A1C in Adults Without a History of Diabetes in the U.S.Diabetes Care, 2009
- Standards of Medical Care in Diabetes—2009Diabetes Care, 2009
- Cardiovascular Outcomes in Trials of Oral Diabetes Medications - A Systematic ReviewArchives of internal medicine (1960), 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older womenDiabetologia, 2007
- Differences in A1C by Race and Ethnicity Among Patients With Impaired Glucose Tolerance in the Diabetes Prevention ProgramDiabetes Care, 2007
- Hemoglobin A1c Predicts Diabetes but Not Cardiovascular Disease in Nondiabetic WomenThe American Journal of Medicine, 2007
- Disparities in HbA1c Levels Between African-American and Non-Hispanic White Adults With DiabetesDiabetes Care, 2006
- Reagent for the Enzymatic Determination of Serum Total Triglycerides with Improved Lipolytic Efficiencycclm, 1984